Fig. 6: SLC7A11 inhibitors suppress in vivo growth of LDHB-deficient KRAS-driven lung tumors.
From: Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer
a, b Tumor development of A549 a and H460 b xenografts treated with erastin (30 mg/kg/day) and SSZ (150 mg/kg/day). c Micro-CT images of LSL-KrasG12D/WT; p53fl/fl mice and LSL-KrasG12D/WT; p53fl/fl; LDHBfl/fl mice at the indicated time points. H&E staining of lung tissue sections after 9-week treatment. Scale bar, 20 μm. d–h Lung volume d, tumor burden e, tumor number f, average tumor size g, and survival fraction h after SSZ treatment. Data are shown as the mean ± s.d. *p < 0.05; **p < 0.01; ***p < 0.001 by one-way ANOVA. NS not significant.
